Effect of Switching from Low-Dose Simvastatin to High-Dose Atorvastatin on Glucose Homeostasis and Cognitive Function in Type 2 Diabetes

References

• Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–696. doi:10.1016/S0140-6736(04)16895-5
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists' (CTT) Collaborators,Kearney PM, Blackwell L, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117–125.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48(3):438–445. doi:10.1016/j.jacc.2006.04.070
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists' (CTT) Collaborators, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–e1143. doi:10.1161/CIR.0000000000000625
   PubMed Web of Science ®Google Scholar
• American Diabetes A. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S111–S134. doi:10.2337/dc20-S010
   PubMedGoogle Scholar
• Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–742. doi:10.1016/S0140-6736(09)61965-6
   PubMed Web of Science ®Google Scholar
• Erqou S, Lee CC, Adler AI. Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis. Diabetologia. 2014;57(12):2444–2452. doi:10.1007/s00125-014-3374-x
   PubMed Web of Science ®Google Scholar
• Hammad MA, Abdo MS, Mashaly AM, et al. The statins effects on HbA1c control among diabetic patients: an umbrella review of systematic reviews and meta-analyses of observational studies and clinical trials. Diabetes Metab Syndr. 2019;13(4):2557–2564. doi:10.1016/j.dsx.2019.07.005
   PubMed Web of Science ®Google Scholar
• Betteridge DJ, Carmena R. The diabetogenic action of statins – mechanisms and clinical implications. Nat Rev Endocrinol. 2016;12(2):99–110. doi:10.1038/nrendo.2015.194
   PubMed Web of Science ®Google Scholar
• FDA. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs. FDA [online] hwfgdduh.
   Google Scholar
• Dormuth CR, Filion KB, Paterson JM, et al. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ. 2014;348:g3244. doi:10.1136/bmj.g3244
   PubMed Web of Science ®Google Scholar
• Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556–2564. doi:10.1001/jama.2011.860
   PubMed Web of Science ®Google Scholar
• Neaton JD, Blackburn H, Jacobs D, et al. Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial. Multiple risk factor intervention trial research group. Arch Intern Med. 1992;152(7):1490–1500. doi:10.1001/archinte.1992.00400190110021
   PubMedGoogle Scholar
• Stemmermann GN, Chyou PH, Kagan A, Nomura AM, Yano K. Serum cholesterol and mortality among Japanese-American men. The Honolulu (Hawaii) Heart Program. Arch Intern Med. 1991;151(5):969–972. doi:10.1001/archinte.1991.00400050113021
   PubMedGoogle Scholar
• Banach M, Rizzo M, Nikolic D, Howard G, Howard V, Mikhailidis D. Intensive LDL-cholesterol lowering therapy and neurocognitive function. Pharmacol Ther. 2017;170:181–191. doi:10.1016/j.pharmthera.2016.11.001
   PubMed Web of Science ®Google Scholar
• Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med. 2000;108(7):538–546. doi:10.1016/S0002-9343(00)00353-3
   PubMed Web of Science ®Google Scholar
• Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med. 2004;117(11):823–829. doi:10.1016/j.amjmed.2004.07.041
   PubMed Web of Science ®Google Scholar
• Hammad MA, Syed Sulaiman SA, Aziz NA, Mohamed Noor DA. Evaluation of statins impacts on cognitive function among diabetic patients. Diabetes Metab Syndr. 2019;13(3):1797–1803. doi:10.1016/j.dsx.2019.04.006
   PubMed Web of Science ®Google Scholar
• Marcum ZA, Vande Griend JP, Linnebur SA. FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother. 2012;10(4):264–271. doi:10.1016/j.amjopharm.2012.05.002
   PubMedGoogle Scholar
• Rojas-Fernandez CH, Goldstein LB, Levey AI, Taylor BA, Bittner V; The National Lipid Association’s Safety Task F. An assessment by the statin cognitive safety task force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S5–S16. doi:10.1016/j.jacl.2014.02.013
   PubMed Web of Science ®Google Scholar
• Thongtang N, Piyapromdee J, Tangkittikasem N, Samaithongcharoen K, Srikanchanawat N, Sriussadaporn S. Efficacy and safety of switching from low-dose statin to high-intensity statin for primary prevention in Type 2 diabetes: a randomized controlled trial. Diabetes Metab Syndr Obes. 2020;13:423–431. doi:10.2147/DMSO.S219496
   PubMed Web of Science ®Google Scholar
• Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699. doi:10.1111/j.1532-5415.2005.53221.x
   PubMed Web of Science ®Google Scholar
• Tangwongchai SPM, Charernboon T, Akkayagorn L, Hemrungrojn S, Phanthumchinda K The validity of Thai version of The Montreal Cognitive Assessment (MoCA-T). International Psychogeriatric Association Conference; Montreal; September 2009, Abstract.
   Google Scholar
• Tunvirachaisakul C, Supasitthumrong T, Tangwongchai S, et al. Characteristics of mild cognitive impairment using the Thai version of the consortium to establish a registry for alzheimer’s disease tests: a multivariate and machine learning study. Dement Geriatr Cogn Disord. 2018;45(1–2):38–48. doi:10.1159/000487232
   PubMed Web of Science ®Google Scholar
• Salthouse TA. What cognitive abilities are involved in trail-making performance? Intelligence. 2011;39(4):222–232. doi:10.1016/j.intell.2011.03.001
   PubMed Web of Science ®Google Scholar
• Tombaugh TN. Trail making test A and B: normative data stratified by age and education. Arch Clin Neuropsychol. 2004;19(2):203–214. doi:10.1016/S0887-6177(03)00039-8
   PubMed Web of Science ®Google Scholar
• Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103(3):357–362. doi:10.1161/01.CIR.103.3.357
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207. doi:10.1056/NEJMoa0807646
   PubMed Web of Science ®Google Scholar
• Bellia A, Rizza S, Lombardo MF, et al. Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy. Atherosclerosis. 2012;223(1):197–203. doi:10.1016/j.atherosclerosis.2012.04.015
   PubMed Web of Science ®Google Scholar
• Her AY, Kim JY, Kang SM, et al. Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism. J Cardiovasc Pharmacol Ther. 2010;15(2):167–174. doi:10.1177/1074248409357922
   PubMed Web of Science ®Google Scholar
• Moutzouri E, Liberopoulos E, Mikhailidis DP, et al. Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. Int J Clin Pract. 2011;65(11):1141–1148. doi:10.1111/j.1742-1241.2011.02779.x
   PubMed Web of Science ®Google Scholar
• Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2015;385(9965):351–361. doi:10.1016/S0140-6736(14)61183-1
   PubMed Web of Science ®Google Scholar
• Thongtang N, Ai M, Otokozawa S, et al. Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am J Cardiol. 2011;107(3):387–392. doi:10.1016/j.amjcard.2010.09.031
   PubMed Web of Science ®Google Scholar
• Bosch J, O’Donnell M, Swaminathan B, et al. Effects of blood pressure and lipid lowering on cognition. Results from the HOPE-3 study. Neurology. 2019;92(13):e1435–e1446. doi:10.1212/WNL.0000000000007174
   PubMed Web of Science ®Google Scholar
• Ott BR, Daiello LA, Dahabreh IJ, et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med. 2015;30(3):348–358. doi:10.1007/s11606-014-3115-3
   PubMed Web of Science ®Google Scholar
• Rej S, Saleem M, Herrmann N, Stefatos A, Rau A, Lanctot KL. Serum low-density lipoprotein levels, statin use, and cognition in patients with coronary artery disease. Neuropsychiatr Dis Treat. 2016;12:2913–2920. doi:10.2147/NDT.S115505
   PubMed Web of Science ®Google Scholar
• Macedo AF, Taylor FC, Casas JP, Adler A, Prieto-Merino D, Ebrahim S. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med. 2014;12:51. doi:10.1186/1741-7015-12-51
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Mach F, Zavitz K, et al. Cognitive function in a randomized trial of Evolocumab. N Engl J Med. 2017;377(7):633–643. doi:10.1056/NEJMoa1701131
   PubMed Web of Science ®Google Scholar
• Mach F, Ray KK, Wiklund O, et al. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39(27):2526–2539. doi:10.1093/eurheartj/ehy182
   PubMed Web of Science ®Google Scholar